Research Topics
| M D PradosSummaryAffiliation: University of California Country: USA Publications
| Collaborators |
Detail Information
Publications
Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapyM D Prados
Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
J Clin Oncol 17:3389-95. 1999..To determine any differences in outcome for patients with anaplastic astrocytoma (AA) treated with adjuvant carmustine (BCNU) versus procarbazine, lomustine, and vincristine (PCV) chemotherapy...
Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapyM D Prados
Department of Neurosurgery, University of California, San Francisco, USA
Pediatr Neurosurg 25:174-81. 1996....
Chemotherapy of brain tumorsM D Prados
Department of Neurosurgery, University of California, San Francisco 94117, USA
Semin Surg Oncol 14:88-95. 1998..As part of a multimodality approach that includes surgery and radiotherapy, chemotherapy has a significant role to play in the treatment of both adults and children with brain neoplasms...
A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404M D Prados
University of California San Francisco, 94143 0372, USA
Int J Radiat Oncol Biol Phys 45:1109-15. 1999....
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimenM D Prados
Department of Neurological Surgery, School of Medicine, University of California, San Francisco, USA
J Neurooncol 32:235-41. 1997..This regimen was safe, able to be delivered in the outpatient setting, and produced prolonged periods of disease stabilization in children with low-grade gliomas...
Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium reportS M Chang
Department of Neurosurgery, University of California, San Francisco, USA
J Clin Oncol 16:2188-94. 1998..To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma...
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiformeM D Prados
Department of Neurosurgery, University of California San Francisco, San Francisco, CA 94143 0372, USA
Int J Radiat Oncol Biol Phys 49:71-7. 2001....
Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium reportS M Chang
University of California Medical Center, San Francisco, USA
J Clin Oncol 17:984-90. 1999..To determine the response rate, time to treatment failure, and toxicity of phenylacetate in patients with recurrent malignant glioma and to identify plasma concentrations achieved during repeated continuous infusion of this agent...
EGFR overexpression and radiation response in glioblastoma multiformeF G Barker
Department of Neurological Surgery, Neuro Oncology Service and Brain Tumor Research Center, University of California, San Francisco, California, USA
Int J Radiat Oncol Biol Phys 51:410-8. 2001..We tested whether these abnormalities correlated with clinical heterogeneity in GM response to radiation treatment...
Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiformeP K Sneed
Department of Radiation Oncology, University of California, San Francisco 94143 0226, USA
Int J Radiat Oncol Biol Phys 40:287-95. 1998..To determine if adjuvant interstitial hyperthermia (HT) significantly improves survival of patients with glioblastoma undergoing brachytherapy boost after conventional radiotherapy...
A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium reportS M Chang
Department of Neurosurgery, University of California Medical Center, San Francisco, California, USA
Cancer 91:417-22. 2001..Secondary objectives were to determine the time period to treatment failure, to evaluate toxicities, and to obtain pharmacokinetic data...
Late radiation injury following hyperfractionated craniospinal radiotherapy for primitive neuroectodermal tumorC Russo
Brain Tumor Research Center of the Department of Neurological Surgery, School of Medicine, University of California, San Francisco, USA
Int J Radiat Oncol Biol Phys 44:85-90. 1999..To document the late radiographic change following hyperfractionated craniospinal radiotherapy for primitive neuroectodermal tumor...
Age and radiation response in glioblastoma multiformeF G Barker
Neuro Oncology Service, Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, USA
Neurosurgery 49:1288-97; discussion 1297-8. 2001..Radiographically assessed tumor response to external beam radiation therapy is an important prognostic factor in GM. We hypothesized that older GM patients might have more radioresistant tumors...
Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgeryE E Graves
Departments of Radiology, University of California, San Francisco 94143, USA
AJNR Am J Neuroradiol 22:613-24. 2001..Evaluation of metabolic changes with proton MR spectroscopy and structural changes with MR imaging improved tissue discrimination and provided correlation with histologic findings...
